Loading...
Please wait, while we are loading the content...
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Roboz, Gail J. Khoury, H. Jean Jabbour, Elias Joseph Session, Wilena Ritchie, Ellen Kelly Miao, Harry H. Faderl, Stefan H. Zheng, Wei Feldman, Eric J. Arellano, Martha Morrison, James Gilmour Ravandi, Farhad |
| Copyright Year | 2015 |
| Abstract | There is no effective treatment for relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We conducted a phase I dose escalation trial of SAR103168, a novel multi-targeted kinase inhibitor with activity against the Src kinase family, the BCR-Abl kinase and several angiogenic receptor kinases. Twenty-nine patients 18-83 years old were treated with SAR103168. Pharmacokinetics was characterized by plasma peak concentration (Cmax) at the end of the infusion, followed by a biphasic decline in the elimination profile. Adverse events were as expected for the patient population and there were no individual toxicities specific to SAR103168. Due to the unpredictable nature of drug exposure, the sponsor decided to discontinue the study prior to reaching the maximum tolerated dose. |
| Starting Page | 395 |
| Ending Page | 400 |
| Page Count | 6 |
| File Format | PDF HTM / HTML |
| DOI | 10.3109/10428194.2014.918970 |
| PubMed reference number | 24794806 |
| Journal | Medline |
| Volume Number | 56 |
| Issue Number | 2 |
| Journal | Leukemia & lymphoma |
| Alternate Webpage(s) | https://open.library.emory.edu/publications/emory:s3t41/pdf/ |
| Alternate Webpage(s) | https://doi.org/10.3109/10428194.2014.918970 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |